Blog

Posts Tagged ‘ovarian cancer’

Ovarian Cancer Early Detection: Screening at Stanford School of Medicine

February 7, 2013

On behalf of the Canary Center at Stanford for Cancer Early Detection and the Stanford Cancer Institute, the Canary Foundation is supporting the search for candidates to participate in the Novel Markers Trial Ovarian Cancer Screening Test. This is an important new research study looking at markers in the blood that may be used as an early detection test for ovarian cancer. If you fit the criteria, please consider joining the effort to reach the vision of living in a world of simple tests that identify and isolate cancer at its earliest, most curable stage.

Candidates are needed who fit the following criteria:

• Healthy women
• Ages 45-80
• Have at least one ovary

If you are willing to donate one tube of blood and fill out a questionnaire once a year for two years, we’re looking for you! If you have three of the following risk factors you may qualify:

• Of Ashkenazi Jewish descent
• Never given birth to a child (this counts as two risk factors)
• Never had a tubal ligation
• Used hormonal contraception (birth control pills) for less than a year in your life

If you are interested in learning more, please contact the research study office at novelmarkers@stanford.edu or call (650) 724-3308. For general information about participant rights, contact 1-866-680-2906.

In Memory: Lawrence Viariseo, Canary Challenge Rider and Cancer Early Detection Advocate

January 29, 2013

Lawrence Viariseo survived a fall off of a tall cliff, and fought a brave battle with cancer before his passing in late January. He raised funds for the Canary Challenge in 2012.  His service is being held February 9, 2013 in Palo Alto, California.

Mr. Viariseo asked for friends or family members to donate to the Canary Challenge in lieu of flowers.

His niece Megan Cox describes him this way, “As you may remember, my uncle was a paraplegic who had beat stage 4 bladder cancer once before.  The doctors at Stanford he felt had saved his life. It meant the world to him to be entering into the challenge in 2012 to give back to those doctors.”

CLICK HERE to make a donation to honor his memory. Please write a personal note if you would like.

Here is a lovely article that ran last year regarding his story, and his commitment to the Canary Challenge.

Cancer Early Detection in 2012: Spirit of the Holidays!

December 13, 2012

We’re so grateful for all of the contributions by scientists, donors, and everyone who participated in the work of cancer early detection in 2012! We sincerely thank our donors, volunteers, scientists, and clinicians for their hard work and support- we couldn’t do it without you! Watch the slideshow below for a look back at all of Canary’s successes and milestones in 2012.

Early Cancer Detection Success Reaps Spirit Awards from Stanford Cancer Institute

December 12, 2012

Canary Founder Don Listwin Honored for Leadership in Early Detection of Cancer Research

Early detection of cancer research represents the heart and soul of our work. Last week, Stanford Cancer Institute bestowed two 2012 Spirit of Hope Awards upon Canary Foundation and on our founder, Don Listwin. We are so honored to be the recipient of this prestigious award, and are grateful for the opportunity to be publicly recognized for the work we do in the field of early detection.

“The commitment to identifying easy and affordable biomarkers to detect cancer when it is small is the driving force behind the work of Canary Foundation,” said Don. “Canary Foundation is honored to be recognized for this work. Within 10 years, we expect and hope to have the tools, technology, tests and the market to allow you to find cancer early where it is most curable.”

Our work is focused on funding scientific discovery into affordable early detection systems such as blood tests and ultrasound imaging in the fields of ovarian, pancreatic, prostate, breast and lung cancer.

“The major way we’re going to make an impact on cancer is early detection and we are thrilled to partner with Canary in this incredible enterprise,” said Stanford Cancer Institute Director Dr. Beverly Mitchell, MD, as she presented the two awards. More »

Nicole Urban on Canary’s Ovarian Cancer Research Program

September 6, 2012

Nicole Urban, Ovarian Cancer Team Co-leader at the Canary Center and investigator at the Fred Hutchinson Cancer Research Center, provides viewers with an overview and the goals for Canary’s Ovarian Cancer Research Program. She also explains how working on collaborative research initiatives with Canary Foundation helps push her research to the next level.

Canary Innovation: Measurable Progress, Real Results

June 4, 2012

Here at Canary Foundation, one of our highest priorities is building a culture of innovation, which we leverage to produce results, save time and lower costs. Both our scientific programs and administrative initiatives reflect these disciplines. We’re proud to report that this approach is helping Canary demonstrate real results in the work we do:

• Canary Foundation developed the first test for a new lung cancer biomarker identified by the team. While tests exist for other biomarkers, there were none for this one, so the team created a test that is now available for any research institution to utilize.
• Our prostate cancer clinical trial called PASS (Prostate Active Surveillance Study) is the only multisite clinical trial for men on active surveillance.  This way of organizing a trial is now being recognized as the most viable way of conducting trials to monitor men with localized, low-risk prostate cancer.
• Canary Foundation’s Tissue Microarray (TMA) project has also led the way in scientific research. Digitized tissue images and a standardized way to conduct digital analyses were the innovations that provide researchers with an online way of sharing and analyzing data that is not the norm in scientific research.
• The Canary Center at Stanford for cancer early detection is the first in the world studying the two-test process of identifying cancer through a blood test and pinpointing the location of the tumor through molecular imaging. More »